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Background: A retrospective utilization study was performed to evaluate utilization patterns 
for enteral nutrition in a university teaching hospital.
Methods: Enteral nutrition was divided into three types according to the nitrogen source, ie, total pro-
tein type [Nutrison Fibre®, Fresubin Energy Fibre®, Fresubin®, Supportan® (a special immunonutrition 
for cancer patients or patients with increased demands for omega-3 fatty acids), Fresubin Diabetes® (a 
diabetes-specific formula), Ensure®]; short peptide type (Peptison®); and amino acid type (Vivonex®). 
A pharmacoeconomic analysis was done based on defined daily dose methodology.
Results: Among hospitalized patients taking enteral nutrition, 34.8% received enteral nutrition 
alone, 30% concomitantly received parenteral nutrition, and 35.2% received enteral nutrition after 
parenteral nutrition. Combined use of the different formulas was observed in almost all hospitalized 
patients receiving enteral nutrition. In total, 61.5% of patients received triple therapy with Nutrison 
Fibre, Fresubin Diabetes, and Supportan. Number of defined daily doses (total dose consumed/
defined daily dose, also called DDDs) of formulas in descending order were as follows: Nutrison 
Fibre, Fresubin Energy Fibre, Fresubin Diabetes . Supportan . Peptison, Ensure . Vivonex, 
Fresubin. The ratio of the cumulative DDDs for the three types of enteral nutrition was 35:2.8:1 
(total protein type to short peptide type to amino acid type). Off-label use of Fresubin Diabetes was 
also observed, with most of this formula being prescribed for patients with stress hyperglycemia. 
Only 2.1% of cancer patients received Supportan. There were 35 cases of near misses in dispensing 
look-alike or sound-alike enteral nutrition formulas, and one adverse drug reaction in an elderly 
malnourished patient who did not receive vitamin K1-enriched enteral nutrition during treatment 
with cefoperazone. After 4 months of the trial intervention, off-label use of Fresubin Diabetes was 
no longer endorsed by the Drug and Therapeutics Committee for nondiabetic patients, and the 
proportion of this formula prescribed for patients with stress hyperglycemia decreased by 20%, 
with a 10-fold increase in the amount of Supportan prescribed for cancer patients. Near misses in 
dispensing look-alike or sound-alike enteral nutrition were successfully abolished, and no severe 
coagulation disorders occurred after prophylactic administration of vitamin K1-enriched enteral 
nutrition in elderly malnourished patients receiving cefoperazone.
Conclusion: This utilization study indicates that continuous quality improvement is necessary 
and that a Drug and Therapeutics Committee can play an important role in promoting rational 
and safe use of enteral nutrition. Appropriateness of this therapy still needs to be improved, espe-
cially in addressing the issues of non-evidence-based combined use of multiple enteral nutrition 
formulas, the relatively high rate of concomitant use of enteral and parenteral nutrition, off-label 
use of diabetes-specific Fresubin Diabetes, insufficient use of Supportan in cancer patients, and 
unnecessary use of Supportan in intensive care patients not suffering from cancer.
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Introduction
Compared with parenteral nutrition, enteral nutrition is less 
expensive and has fewer complications. If the gut works, 
enteral nutrition is preferred.1 Compared with parenteral 
nutrition, the cost savings associated with reduction in risk 
of adverse events and decrease in duration of hospital stay 
using enteral nutrition average nearly $4000 per patient in 
the US. Shifting 10% of adult patients from enteral nutrition 
to parenteral nutrition will save $35 million annually.2
Enteral nutrition formulas can be divided into three 
categories according to the nitrogen source, ie, total protein 
type, short peptide type, and amino acid type. Inappropriate 
ordering of enteral nutrition by physicians leads to unneces-
sary financial expense and decreased therapeutic efficacy, as 
well as an increased likelihood of adverse events. Therefore, 
it is necessary to be able to identify and monitor current 
prescribing patterns for enteral nutrition. However, no lit-
erature on enteral nutrition utilization patterns, especially 
the different types of enteral nutrition, was identifiable on 
the PubMed database. Therefore, we examined clinical risks 
and prescribing practices for enteral nutrition in hospitalized 
patients in a large university teaching hospital and inves-
tigated whether the three types of enteral nutrition were 
prescribed appropriately based on formula characteristics 
and patient disease status.
Materials and methods
Data collection
This retrospective drug utilization study was performed in 
a tertiary university teaching hospital with 2200 beds. Data 
were obtained from the hospital information system and 
processed using Visual FoxPro version 9.0. Records of new 
or serious adverse events, and near misses associated with 
enteral nutrition, were audited retrospectively.
Eight enteral nutrition formulas were included: total 
protein type [Nutrison Fibre®, Fresubin Energy Fibre®, 
Fresubin®, Supportan® (a special immunoenhancing formula 
for cancer patients or those with increased demands for 
omega-3 fatty acids), Fresubin Diabetes® (a diabetes-specific 
formula), Ensure®]; short peptide type (Peptison®); and amino 
acid type (Vivonex®). The nutritional components of these 
formulas are shown in Table 1.
Statistical analysis
A descriptive analysis was performed on all prescriptions of 
enteral nutrition for patients hospitalized in 2011. A defined 
daily dose (DDD) methodology was used.3 The defined daily 
doses for enteral nutrition were derived from package inserts 
and calculated based on the daily dose of nutritional supple-
ments. Number of defined daily doses (also called DDDs) 
and daily expenditure were estimated using the following 
equations:
  DDDs = Total dose consumed/DDD 
  Daily expenditure = Overall expenditure/DDDs 
Differences between patient groups were tested for statisti- 
cal significance using the Student’s t-test. A P value , 0.05 
was considered to be statistically significant.
Results
Combination use
There were 2928 hospitalized patients taking enteral nutrition 
in 2011. Of these, 1020 (34.8%) received enteral nutrition 
alone, 878 (30%) patients received concomitant parenteral 
nutrition, and 1030 (35.2%) received enteral nutrition fol-
lowing parenteral nutrition. The difference in age between 
patients receiving enteral nutrition alone and those receiving 
enteral and parenteral nutrition was not statistically sig-
nificant (P . 0.05). The parenteral nutrition therapies were 
categorized according to energy and substitutes, ie, normal, 
high stress, and fluid-restricted. A team consisting of spe-
cialized doctors, nurses, clinical pharmacists, and dietitians 
assessed each patient’s clinical status and decided on which 
parenteral nutrition formula to use. On average, 160 bags of 
parenteral nutrition mixtures were prescribed, most of which 
consisted of glucose, amino acids, lipids, water, electrolytes, 
essential vitamins, minerals, and trace elements. About 
60 three-chamber bags of standard parenteral nutrition-based 
mixtures (Kabiven®, Fresenius Kabi AB, Sweden) were used 
in intensive care units every day.
Combination use of multiple formulas was documented 
in 99.7% of hospitalized patients receiving enteral nutrition 
(Table 2). The relative percentage of different combina-
tion modes was as follows: triple therapy (72.7%) . dual 
therapy (24.8%) . quadruple therapy (2.2%). The age 
difference between patients on monotherapy, dual therapy, 
triple therapy, and quadruple therapy with different enteral 
nutrition formulas was not statistically significant (P . 0.05). 
Surprisingly, 61.5% of patients on enteral nutrition received 
triple therapy of Nutrison Fibre, Fresubin Diabetes, and 
Supportan.
Pharmacoeconomic data
Pharmacoeconomic data for the eight enteral nutrition 
formulas are shown in Table 3. The values of DDDs in 
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descending order were: Nutrison Fibre, Fresubin Energy 
Fibre, and Fresubin Diabetes . Supportan . Peptison, and 
Ensure . Vivonex and Fresubin. The ratio of cumulative 
DDDs for the three types of enteral nutrition was 35:2.8:1 
(total protein type to short peptide type to amino acid type), 
and the order of daily expenditure was: Vivonex . Pepti-
son . Supportan . Fresubin Diabetes, Fresubin Energy 
Fibre, and Fresubin . Ensure.
Enteral nutrition according to ward type
Nutrison Fibre and Fresubin Energy Fibre were prescribed 
more frequently in intensive care, burns, neurology, and 
neurosurgery wards than in other wards (80% versus 20%). 
Off-label use of Fresubin Diabetes was commonly observed. 
Of 331 patients receiving this formula, only four (1.2%) 
patients suffered from diabetes. Most of this formula was 
prescribed for patients with potential stress hyperglycemia. 
The amount of Supportan consumed in oncology wards 
with 9600 person-time inpatients annually accounted for 
6.9% of total consumption of this formula in this hospital. 
Only 2.1% of cancer patients received Supportan. Seven of 
the enteral nutrition formulas (ie, Nutrison Fibre,   Fresubin 
Energy Fibre, Supportan, Fresubin Diabetes, Ensure, 
Peptison, and Vivonex) were prescribed more frequently 
in intensive care wards than in non-intensive care wards. 
Consumption in intensive care as a proportion of total 
consumption in all wards was: 57.0% (Nutrison Fibre), 
47.5% (Fresubin Energy Fibre), 37.9% (Supportan), 53.5% 
(Fresubin Diabetes), 20.7% (Ensure), 54.9% (Peptison), 
and 74.7% (Vivonex).
The top seven wards using the enteral nutrition formulas, 
based on cumulative DDDs, were intensive care, geriatrics, 
burns, neurology, neurosurgery, general surgery, thoracic 
surgery, and oncology. Cumulative DDDs of all enteral 
nutrition formulas in intensive care accounted for 48.7% of 
the sum of DDDs for all enteral nutrition formulas in this 
hospital. Relative percentages for the other six wards were: 
geriatrics (11.3%), burns (10.5%), neurology and neurosur-
gery (9.7%), general surgery (6.0%), thoracic surgery (2.5%), 
and oncology (2.0%).
Near misses and adverse events
In 2011, there were 35 cases of near misses when dispens-
ing look-alike or sound-alike formulas of enteral nutrition. 
Fortunately, all these near misses made by pharmacists were 
detected and reported by clinical nurses.
Except for mild diarrhea, new or serious adverse 
events attributable to enteral nutrition were not detected 
Table 1 Nutritional composition of eight enteral nutrition formulas
Type of enteral nutrition
Total protein type Short  
peptide type
Amino  
acid type
Nutrison  
Fibre® 
(500 mL)
Fresubin  
Energy Fibre®  
(500 mL)
Fresubin® 
(500 mL)
Supportan® 
(200 mL)
Fresubin  
Diabetes® 
(500 mL)
Ensure® 
(400 g)
Peptison® 
(500 mL)
Vivonex® 
(80.4 g)
Energy density  
(kCal/mL)
1.5 1.5 1.0 1.3 1.0 1.0 
(55.8 g/250 mL)
1.0 1.0 
(80.4 g/300 mL)
NPC:N 133:1 167:1 184:1 139:1 165:1 174:1 172.4:1 138:1
Pro:Fat:Car 16:35:49 15:35:50 15:30:55 18:50:32 15:32:53 14:32:54 16:9:75 15:3:82
Protein (g) 30 28 19 11.7 17 63.6 20 (hydrolyzed  
whey protein)
14.2 (crystalline 
amino acid)
Carbohydrates  
(g)
92.5 94 69 20.8 60 242.8 88 63
Lipids (g) 29.5 29 17 14.4 16 63.6 8.5 0.51
Fiber (g) 7.5 10 0 2.6 7.5 0 0 0
Omega-3 fatty  
acids (g)
1.53 0 0 0.6 0 0 0 0
Osmolality  
(mOsm/L)
300 320 250 330 320 320 470 610
Abbreviations: NPC, nonprotein calorie to nitrogen ratio; Pro, protein; Car, carbohydrate.
Table 2 Combination use of different enteral nutrition formulas 
in hospitalized patients
Combination mode n Relative %
Total 2928
Triple therapy 2129 72.7
Dual therapy 726 24.8
Quadruple therapy 63 2.2
Monotherapy 9 0.3
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in 2011. However, there was one case of an adverse drug 
reaction in an elderly malnourished patient not receiving 
  vitamin   K1-  enriched enteral nutrition during treatment with 
  cefoperazone. This was a 98-year-old bedridden tube-fed 
patient with an acute bacterial exacerbation of chronic 
bronchitis and cerebrovascular disease and suffering from 
a severe coagulation disorder induced by cefoperazone. 
A consultation was requested with a clinical pharmacist 
who identified that the cause of this adverse event was 
vitamin K deficiency caused by eradication of vitamin 
K-producing intestinal bacteria or inhibition of action of 
vitamin K1 as a result of enteral nutrition given without 
vitamin K supplementation. The coagulopathy was cor-
rected by administration of vitamin K1, cessation of the 
antibiotic, and addition of vitamin K-enriched high-density 
Nutrison Fibre (20 µg/500 mL). Prophylactic administra-
tion of vitamin K1 is now recommended for all elderly 
malnourished patients being treated with cefoperazone in 
this hospital.
Preliminary intervention efforts
The appropriateness of enteral nutrition attracted the atten-
tion of the Drug and Therapeutics Committee at our hospital 
in February 2012. A Plan-Do-Check-Act cycle was used for 
continuous quality improvement.4 After 4 months of this 
preliminary intervention, off-label use of Fresubin Diabe-
tes was no longer approved by the Drug and Therapeutics 
Committee for nondiabetic patients, and the amount of this 
formula prescribed for patients with stress hyperglycemia 
decreased by 20%. There was also a 10-fold increase in the 
amount of Supportan prescribed for cancer patients. Near 
misses in dispensing of look-alike or sound-alike enteral 
nutrition were successfully abolished, and no cases of 
cefoperazone-induced severe coagulation disorder occurred 
when prophylactic vitamin K1-enriched enteral nutrition 
was administered to elderly malnourished patients receiving 
cefoperazone.
Discussion
Combination of enteral and parenteral 
nutrition
Clinical studies have shown that a combination of enteral 
and parenteral nutrition can improve the clinical outcome in 
intensive care patients, including reducing morbidity, length 
of stay, and recovery time, as well as improving quality of 
life and decreasing health care costs.5–7 A meta-analysis 
has shown that 80% of critically ill patients can receive 
enteral nutrition alone, 10% can receive combined enteral 
and parenteral nutrition, and the remaining 10% need total 
parenteral nutrition.8 Our survey indicated that one-third of 
patients received combined enteral and parenteral nutrition. 
The relatively high rate of combination use of parenteral 
and enteral nutrition suggests that enteral nutrition alone 
may be inadequate.
No evidence for combined use of multiple enteral nutri-
tion formulas is available in the PubMed database, so further 
investigations addressing this issue need to be performed. 
Triple therapy with one bottle each of Nutrison Fibre, 
Fresubin Diabetes, and Supportan costs about 600 Chinese 
Yuan Renminbi (CNY) per day and was considered to be 
overuse of medication, the underlying reasons for which are 
unclear. A pharmacoeconomic study on this issue needs to 
be performed in the future.
Pharmacoeconomic indices
The DDDs indicates trends in drug use, such that the higher 
DDDs of a therapy, the more frequent its utilization. In our 
study, the DDDs for Nutrison Fibre and Fresubin Energy 
Fibre ranked first and second, respectively, which may 
be due to the characteristics of the two formulas, ie, their 
Table 3 Pharmacoeconomic indices of eight enteral nutrition formulas for hospitalized patients
Type Drug name DDD DDDs Total expenditure 
(CNY)
Daily expenditure 
(CNY)
TP Nutrison Fibre® 1333 mL 9078 1,929,000 212.5
TP Fresubin Energy Fibre® 500 mL 8874 675,000 76.1
TP Fresubin Diabetes® 500 mL 8839 819,000 92.6
TP Supportan® 1200 mL 4970 1,714,000 345
TP Ensure® 171 g 2430 75,000 30.8
TP Fresubin® 1000 mL 684 55,000 80.4
SP Peptison® 2000 mL 2743 1,099,000 400.9
AA Vivonex® 482.4 g 992 442,000 445.6
Abbreviations: DDD, defined daily dose; DDDs, total dose consumed/DDD; daily expenditure, overall expenditure/DDD; TP, total protein; SP, short peptide; AA, amino 
acid; CNY: Chinese Yuan Renminbi.
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high energy density (1.5 kCal/mL), high protein content 
(56–60 g/1000 mL), and amount of added dietary fiber 
(15–20 g/1000 mL). Peptison and Vivonex were found to 
have markedly lower DDDs compared with total protein type 
enteral   nutrition, which may be attributed to the higher price 
and defined daily doses of these two formulas. The ratio of 
cumulative DDDs for the three types of enteral nutrition was 
35:2.8:1 (total protein type to short peptide to amino acid 
type), reflecting formula characteristics. To our knowledge, 
ours is the first report of enteral nutrition consumption in 
clinical practice.
Enteral nutrition consumption according 
to type of ward
Table 4 summarizes the strengths and shortcomings of 
each of the eight enteral nutrition formulas investigated 
in this study. Nutrison Fibre and Fresubin Energy Fibre 
are concentrated formulas, and more suitable for patients 
who require water restriction because of brain injury or 
heart failure, as well as for patients with high energy and 
protein demands. Intensive care, burns, neurology, and 
neurosurgery wards accounted for about 80% of total con-
sumption of Nutrison Fibre and Fresubin Energy Fibre. 
This utilization pattern may also reflect the characteristics 
of the two formulas.
Fresubin Diabetes is a diabetes-specific formula, as 
described in its package insert. It can reduce glucose load 
in patients with diabetes or glucose intolerance. Intensive 
care, geriatrics, and burns wards accounted for 80% of total 
consumption of Fresubin Diabetes. A literature review did 
not find evidence of off-label use of this formula (ie, for 
prevention of potential stress hyperglycemia). Although well 
controlled studies have demonstrated that hyperglycemia is 
an indicator of poor clinical outcome in inpatients, further 
studies are needed to determine whether Fresubin Diabetes 
helps to improve glycemic control.
Supportan is a high-fat, high-energy density, low carbo-
hydrate formula which is designed based on the metabolic 
characteristics of tumor cells. (ie, a high glucose demand 
compared with benign cells of the same tissue) and is thus 
specific for cancer patients with malnutrition.9 It is also 
indicated for patients with an increased demand for omega-3 
fatty acids. Our survey found that only 2.1% of cancer 
patients received Supportan, and the amount of this formula 
consumed in oncology wards accounted for only 6.9% of the 
total amount consumed in our hospital. Cumulative DDDs of 
all enteral nutrition formulas in oncology wards accounted 
for only 2% of the cumulative DDDs of the eight enteral 
nutrition formulas in all wards. The prescribing patterns for 
Supportan as well as other enteral nutrition formulas in the 
oncology wards indicated inadequate awareness of clinical 
nutrition support for cancer patients.
Consumption of Supportan in the intensive care setting 
accounted for 37.9% of total consumption by all wards, which 
may reflect the beneficial effects of omega-3 fatty acids in 
critically ill patients, ie, a reduced incidence of complications 
and shorter hospitalization times.10 However, more research is 
needed before definitive recommendations can be made con-
cerning the routine use of omega-3 fatty acids in critically ill 
patients.11 Further, Nutrison Fibre contained a higher defined 
daily dose-based quantity of omega-3 fatty acids (4.1 g versus 
3.6 g) and was less expensive than Supportan (212.5 CNY 
versus 345 CNY, respectively). Therefore, routine use of 
Supportan in intensive care patients is not a cost-effective 
option, and doctors need to consider medication costs when 
prescribing for patients who do not have cancer.
Peptison is a peptide-based formula. Peptide-based enteral 
nutrition is easily used and more likely to improve nutritional 
status and immune function and thereby enhance postopera-
tive recovery. The amount of Peptison consumed in intensive 
care and general surgery wards accounted for 54.9% and 
17.7%, respectively, of the total amount consumed. Again, 
the prescribing pattern for Peptison reflects its characteristics. 
From the perspective of pharmacoeconomics, a total protein-
based formula instead of a short peptide-based formula is the 
preferred choice for patients with normal or almost normal 
digestion and absorption in the gastrointestinal tract.
Vivonex is an amino acid-based formula and suitable for 
patients with severe metabolic disorders and gastrointestinal 
dysfunction. The amount of Vivonex consumed in intensive 
care accounted for 74.7% of the total amount consumed in the 
hospital, with the data yet again reflecting the characteristics 
of this formula.
Adequate nutritional support is important in the com-
prehensive management of patients in intensive care. Early 
administration of enteral nutrition maintains gastrointestinal 
integrity and function, thus minimizing the translocation of 
organisms, and reducing complication rates, length of stay 
in intensive care, and risk of death. American Society for 
Parenteral and Enteral Nutrition guidelines highlight enteral 
nutrition as the preferred route of feeding over parenteral 
nutrition in critically ill patients who require nutrition 
support, starting within the first 24–48 hours following 
admission to intensive care.12 The prescribing patterns 
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Table 4 The strength and shortcomings of eight enteral nutrition formulas
Nitrogen  
source
Enteral  
nutrition
Strength Shortcomings
Total  
protein
Nutrison  
Fibre® 
(500 mL)
•    It is more suitable for patients who need water restriction  
and patients with high demand of energy and protein.
•    It can be used for patients with diabetes mellitus.
•    It can be used for patients over 1 year old.
•    It contains more DDD-based quantity of omega-3 fatty  
acid which may have beneficial effects in critically ill  
patients than Supportan®.
•    It is not suitable for patients requiring low 
residue diet.
•    Monitoring of fluid balance is required during 
the course of treatment.
Fresubin  
Energy  
Fibre® (500 mL)
•    It is more suitable for patients who need water restriction  
and patients with high demand of energy and protein.
•    The fiber-rich formula facilitates the maintenance  
of intestinal structure and function, and thus it is suitable  
for long-term application.
•    It is not suitable for patients requiring low 
residue diet.
•    Monitoring of fluid balance is required during 
the course of treatment.
•    It is only indicated for adult patients.
Fresubin® 
(500 mL)
•    This product does not contain dietary fiber so that it  
can be used for serious gastrointestinal stenosis patients,  
patients with intestinal fistula and bowel preparation  
before the colonoscopy.
•    It is not suitable for patients with high demand 
of energy and protein.
•    Long-term use of this product is only suitable 
for patients who should not take dietary fiber.
Ensure® 
(400 g)
•    It is the cheapest product with the lowest daily  
expenditure among 8 formulas.
•    It can be used for children over 4 years old besides adults.
•    Due to powder characteristics it is convenient for storage.  
Unlike other emulsions which can be kept up to 24 hours  
in a refrigerator after opening, it can be stored at room  
temperature for three weeks once it has been opened.
•    It is low-residue formula.
Supportan® 
(200 mL)
•    It is a special immunonutrition for cancer patients  
or patients with increased demands for omega-3 fatty acids.
•    Routine use of Supportan® in ICU is not an 
economic choice.
•    It is only indicated for adult patients.
•    It is disease-specific formula and thus there are 
strict indications.
Fresubin  
Diabetes® 
(500 mL)
•    This diabetes specific formula can reduce glucose load  
in patients with diabetes or glucose intolerance.
•    It is rich in dietary fiber content and helps to maintain  
the function of gastrointestinal tract.
•    It is disease-specific formula and thus there are 
strict indications.
Short  
peptide
Peptison® 
(500 mL)
•    The peptides can be easily absorbed by enzyme  
hydrolysis in intestinal brush border.
•    It may decrease inflammation and increase antioxidant  
defenses in elderly patients with ischemic stroke, compared to 
casein containing formula (eg, Nutrison Fibre®).
•    It can be indicated for diabetes.
•    Compared with total protein-based formula, 
it is not economic for patients with normal or 
almost normal gastrointestinal digestion and 
absorption function.
Amino  
acid
Vivonex® 
(80.4 g)
•    It is amino acid based formula which can be directly  
absorbed via enteral mucosa. It is suitable for patients  
with severe metabolic disorders and gastrointestinal 
dysfunction.
•    Due to powder characteristics it is convenient for storage.
•    The formula has no residue.
•    It is the most expensive formula with the highest 
daily expenditure.
•    It has obviously higher osmolality and thus 
theoretically higher occurrence of osmotic 
diarrhea compared with total protein-based and 
peptide-based formulas.
•    It is not indicated in children below 10 years old.
in intensive care in our survey indicate adequate enteral 
  nutrition support.
Lam et al concluded that, in burns patients, early enteral 
nutrition had better effects than total parenteral nutrition 
on immune and metabolic function and reduces the rates 
of complications and mortality.13 Cumulative DDDs of all 
enteral nutrition formulas in the burns ward accounted for 
10.5% of the sum of DDDs for all enteral nutrition formulas 
in all wards, reflecting good awareness of the need for enteral 
nutrition support in burns patients.
Malnutrition is common both before and after stroke, 
with dysphagia adding to nutritional risk. Further, malnu-
trition leads to prolonged length of hospital stay, reduced 
functional status, and poorer survival. Early enteral nutrition 
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supplements can significantly improve nutritional intake in 
undernourished stroke patients.14 The sum of DDDs for the 
eight enteral nutrition formulas consumed in the neurology 
ward ranked fourth. An enteral formula containing hydro-
lyzed whey protein can decrease inflammation and increase 
antioxidant defense in elderly patients with ischemic stroke 
to a greater extent than a standard enteral formula contain-
ing casein as the protein source. Whey protein-based enteral 
nutrition is superior to casein-based enteral nutrition for 
patients with stroke.15 However, hydrolyzed whey protein-
enriched Peptison was prescribed far less often than casein-
enriched Nutrison Fibre at our hospital, with the ratio of 
the DDDs for these two formulas being 15:1 (casein versus 
hydrolyzed whey protein). The daily expenditure on Peptison 
was nearly twice that of Nutrison Fibre, which may explain 
the utilization patterns seen for the two formulas in stroke 
patients.
Conclusion
In this study, clinical enteral nutrition utilization patterns 
were evaluated in a university teaching hospital. Generally, 
clinicians had good awareness of the need for nutrition sup-
port, with adequate use in intensive care, geriatrics, burns, 
neurology, and neurosurgery wards, and an appropriate ratio 
for use of the three different types of enteral nutrition in 
line with formula characteristics. However, ongoing quality 
improvement is necessary, in particular to address issues such 
as non-evidence-based combination use of multiple enteral 
nutrition formulas, a relatively high rate of concomitant use 
of enteral and parenteral nutrition, off-label use of diabetes-
specific Fresubin Diabetes, insufficient use of Supportan in 
cancer patients, and the costly use of Supportan in intensive 
care patients without cancer.
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